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Purpose: We assessed the long-term efficacy and safety of human retinal progenitor
cells (hRPC) using established rodent models.
Methods: Efficacy of hRPC was tested initially in Royal College of Surgeons (RCS)
dystrophic rats immunosuppressed with cyclosporine/dexamethasone. Due to
adverse effects of dexamethasone, this drug was omitted from a subsequent dose-
ranging study, where different hRPC doses were tested for their ability to preserve
visual function (measured by optokinetic head tracking) and retinal structure in RCS
rats at 3 to 6 months after grafting. Safety of hRPC was assessed by subretinal
transplantation into wild type (WT) rats and NIH-III nude mice, with analysis at 3 to 6
and 9 months after grafting, respectively.
Results: The optimal dose of hRPC for preserving visual function/retinal structure in
dystrophic rats was 50,000 to 100,000 cells. Human retinal progenitor cells integrated/
survived in dystrophic and WT rat retina up to 6 months after grafting and expressed
nestin, vimentin, GFAP, and bIII tubulin. Vision and retinal structure remained normal
in WT rats injected with hRPC and there was no evidence of tumors. A comparison
between dexamethasone-treated and untreated dystrophic rats at 3 months after
grafting revealed an unexpected reduction in the baseline visual acuity of
dexamethasone-treated animals.
Conclusions: Human retinal progenitor cells appear safe and efficacious in the
preclinical models used here.
Translational Relevance: Human retinal progenitor cells could be deployed during
early stages of retinal degeneration or in regions of intact retina, without adverse
effects on visual function. The ability of dexamethasone to reduce baseline visual
acuity in RCS dystrophic rats has important implications for the interpretation of
preclinical and clinical cell transplant studies.
Introduction
In retinitis pigmentosa, retinal degeneration occurs
due to numerous different mutations, mainly in the
rod photoreceptors,1 but also in the supporting retinal
pigment epithelium cells.2 Cones die secondarily to
rods and the loss of vision in this disease usually
progresses from periphery to center, with associate
remodeling of downstream visual circuits.3,4 At
present, there is no treatment for this condition or
other diseases where photoreceptors degenerate.
However, one promising avenue arising from work
in basic research involves the transplantation of
retinal progenitor cells to slow progression of the
disease or restore visual function.5–8
Various sources of cells that can replace photore-
ceptors are being investigated, including those from
fetal, embryonic stem cell, and induced pluripotent
stem cell sources.9–12 In addition to photoreceptor
progenitor cells, other cell types also have shown
promise in their ability to slow the rate of retinal
degeneration.13–15
Human retinal progenitor cells (hRPC) that can be
expanded in a progenitor state and then differentiated
into retinal cells before or following transplantation
are an attractive solution to produce a sufficient
volume of donor cells for therapeutic application.
These cells are obtained from human fetal eyes at 16
to 18 weeks of gestation; a time at which retinal
differentiation has been well defined.16,17 It has been
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shown that hRPC can be expanded for multiple
passages in an undifferentiated state and then express
photoreceptor markers (opsins) upon differentiation
in vitro or following subretinal transplantation.12,18,19
Importantly, the expansion phase of hRPC can be
extended significantly under low oxygen conditions,
generating a scalable cell source suitable for wide-
spread clinical application.19
We tested the preclinical safety and efficacy of a
hRPC line (GS089), which had been expanded to
passage 9 under low oxygen conditions under good
manufacturing practice (GMP) conditions. The safety
of hRPC was tested in NIH-III nude mice, while the
effective dosage range of these cells was examined
using the Royal College of Surgeons (RCS) dystro-
phic rat model. These rats experience a degeneration
of rods and cones over the first 3 months of life due to
the same genetic defect as a group of patients with
retinitis pigmentosa,2,3,20 and are a well-established
preclinical model for testing the ability of human cells
to slow the course of retinal degeneration.14,15
Importantly, previous work has shown that a
clinically applicable dose can be established by
conducting a dose-ranging study in these rats.15,21
In addition, we also conducted an experiment in
wild type (WT) rats to establish if a single efficacious
dose of hRPC would have any adverse effects on
normal retinal structure and vision. We reported that
hRPC are safe and efficacious in these models and
that this cell line holds significant potential to slow
the rate of vision loss in retinal degenerative disease.
We also reported a rather unexpected role for
dexamethasone treatment in accelerating the deterio-
ration of baseline visual function in RCS dystrophic
rats, which may be linked to a suppression of
microglial/macrophage infiltration of the outer retina.
Methods
Isolation and Preparation of hRPC
The hRPC line used in this study (GS089) was
isolated from the retinae of a single human fetus at 16
weeks of gestation in compliance with the Declaration
of Helsinki. Material was obtained from Advanced
Bioscience Resources (Alameda, CA), under the
quality and safety guidelines for Food and Drug
Administration (FDA) Good Tissue Practice condi-
tions. The isolation and culture of hRPC has been
described in detail previously.12,19,22 In brief, the
neural retina was dissociated with collagenase I and
expanded at 378C under low oxygen conditions (3%
O2, 5% CO2, 100% humidity) on human fibronectin-
coated flasks in Ultraculture medium (Lonza, Wal-
kersville, MD) supplemented with 20 ng/mL human
epidermal growth factor (EGF; Peprotech, Rocky
Hill, NJ), 10 ng/mL human basic fibroblast growth
factor (bFGF; Peprotech), and 2 mM L-glutamine
(Invitrogen, Carlsbad, CA). Cells were passaged at
80% confluence and reseeded at a density of 23 104
cells/cm2.
The hRPC batches used for transplantation into
rats were produced at ReNeuron’s Guildford, UK
laboratories from a P8 GMP working cell bank,
which was thawed and cultured in human fibronectin-
coated T500 flasks at 3% O2 as described above. After
72 hours in culture, hRPC were harvested with
TrypZean (Sigma-Aldrich Corp., St. Louis, MO),
followed by defined trypsin inhibitor (Gibco/Thermo
Fisher Scientific, Waltham, MA) and Benzonase
(Merck & Co., Rockville, MD). The P9 GS089 hRPC
then were formulated at 1 3 105 cells/lL in vehicle
(Ca2þ, Mg2þ-free HBSS containing 0.5 mM N-acetyl-
L-Cysteine [HBSS-NAC]) on the morning of each
transplantation day and shipped to UCL-Institute of
Ophthalmology (UCL-IOO). This stock solution was
either used undiluted for the 2 3 105 (200 K) dosage
group (2 lL per rat), or diluted appropriately with
vehicle to generate cell suspensions for the 1 3 105
(100 K), 5 3 104 (50 K), and 1 3 104 (10 K) dosage
groups. On each surgery day, the cells were counted
and assessed for viability upon completion of
transplants. This was done using a hemocytometer,
where cell viability was determined by calculating the
percentage of living cells that exclude trypan blue.
Using this method, cell viability was consistently
.70% upon completion of transplants.
Animals
The animals used in this study were either
pigmented RCS dystrophic rats, pigmented WT
(nondystrophic) Lister Hooded rats, or pigmented
Crl:NIH-LystbgFoxn1nuBtkxid homozygous nude mice
(NIH-III). The RCS dystrophic rats were bred in-
house at UCL-IOO, while WT rats and NIH-III mice
were purchased from a commercial supplier (Charles
River Laboratories, Wilmington, MA). All RCS
dystrophic rats were 23 to 25 days old on the day of
transplantation, an age range that has been used
previously to measure human cell-derived visual
preservation in this model.13,23 All WT rats were 28
to 29 days old and the NIH-III mice were 35 to 42
days old on the day of transplantation, an age that
corresponds with the maturation of visual function in
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rodents.24,25 Animals were maintained in a 12-hour
light/dark cycle, with food and water available ad
libitum. All procedures were performed in accordance
with UK Home Office regulations and adhered to the
ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Subretinal Transplantation
The procedure used for subretinal transplantation
of human cells has been described in detail previous-
ly23,26 and involved injection of hRPC (2 lL total
volume for rats and 1 lL for NIH-III mice) using a 30
to 34 gauge Hamilton needle into the subretinal space
of anesthetized animals. Successful subretinal injec-
tions resulted in a clear retinal detachment in the
dorsal retina and any evidence of inadvertent
intravitreal injection or retinal hemorrhage was noted.
Experimental animals were injected in counterbal-
anced batches and injections groups were randomized
within individual cages. For a detailed injection
method please see additional methods in the supple-
mentary material.
Single Dose Subretinal Injection with
Dexamethasone Treatment
Previous studies have shown poor xenograft
survival in the absence of dexamethasone treat-
ment,23,27–29 with successful preclinical studies in
RCS dystrophic rats using a 2-week course of
dexamethasone to control acute inflammatory re-
sponses.14,15 As such, we first wanted to establish this
dexamethasone protocol in our laboratory and test
the ability of a single dose of hRPC to preserve vision
and retinal structure in dystrophic rats 3 months after
grafting.
For this initial experiment, a total of 37 dystrophic
rats received either 5 3 104 hRPC in 2 lL (50 K
group, n¼22) or 2 lL of the HBBS-NAC vehicle (0 K
group, n¼ 15). This concentration of cells was chosen
because 50,000 human cells have been shown previ-
ously to be optimal for preserving visual function in
RCS dystrophic rats.15 In accordance with the
published preclinical protocol of Lu et al.15 and
McGill et al.,14 the rats received an intraperitoneal
(IP) injection of dexamethasone at 1.6 mg/kg/day
(Organon Pharmaceuticals USA, Inc., Roseland, NJ)
every day for 2 weeks following surgery and remained
on oral cyclosporine A (210 mg/L) from 2 days before
surgery until the end of the study. Visual function was
assessed in these animals at 12 weeks after grafting
using the optokinetic response (OKR) and photore-
ceptor preservation was quantified by measuring
outer nuclear layer (ONL) thickness in histologic
sections following sacrifice at 14 weeks after grafting
(n¼ 7 animals from the 50 K group and n¼ 4 animals
from the 0 K group).
Dose Ranging Study without
Dexamethasone Treatment
During the single-dose study described above, a
significant proportion (~38%) of animals experienced
signs of ill health from 1 week after injection and were
removed from the study. As the affected animals came
from hRPC- and vehicle-treated groups, this adverse
reaction was attributed to the dexamethasone injec-
tions and it was deemed ethically unacceptable to
repeat this protocol for the dose-ranging study. As
such, given that human cells have been reported to
survive and preserve vision in RCS dystrophic rats on
oral cyclosporine alone,28–30 we decided to proceed
with a dose-ranging study in the absence of dexa-
methasone.
A total of 64 dystrophic rats were divided into 5
different treatment groups incorporating vehicle (0 K,
n¼ 13) and 4 hRPC doses: 13 104 (10 K, n¼ 13), 53
104 (50 K, n¼ 13), 13105 (100 K, n¼12), and 23105
(200 K, n ¼ 13). In addition, to assess any potential
adverse impact of hRPC on normal vision and retinal
structure, we also included a group of WT rats, which
received subretinal injections of either 53104 (50 K, n
¼ 15) hRPC or vehicle (0 K, n ¼ 15). All animals
remained on oral cyclosporine A (210 mg/L) from 2
days before surgery until the end of the study and
received a single 2-lL injection into the left eye, with
the right eye remaining uninjected. All animals were
tested by OKR at 12 weeks and n¼ 5 rats per group
were euthanized for histology at 14 weeks after
grafting. The remaining animals in each group then
were retested for OKR at 26 weeks after grafting
before being euthanized for histology.
Measurement of the OKR
A single observer who was blinded to experimental
groups performed all behavioral OKR testing. This
was done using an established method that distin-
guishes visual function emanating from left and right
eyes by measuring the total amount of time spent
head tracking in the clockwise and anticlockwise
direction respectively.13 The OKR data presented
represent total time spent tracking per eye (over 2
minutes) in response to each of 3 different grating
frequencies: Coarse (0.125 cycles/deg [C/D]), interme-
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diate (0.25 C/D), or fine (0.5 C/D). An on-screen
timer was used during video analysis, a method
validated previously in the laboratory for its ability to
detect statistically significant differences in OKR.23
For full details of the OKR method used, please see
additional methods in the supplementary material.
Tissue Collection and Immunohistochemistry
Rats were deeply anesthetized with sodium pento-
barbital (Euthatal; 800 mg/kg) before perfusion
fixation with 60 mL 0.1 M PBS followed by 70 mL
of 4% paraformaldehyde (PFA) in 0.1 M PBS. All
eyes then were removed and orientated by inclusion of
the dorsal eyelid. Tissue was post-fixed in 4% PFA
overnight and cryoprotected in 0.1 M PBS containing
30% sucrose (both overnight at 48C). Eyes then were
frozen-embedded in OCT compound (TissueTek) and
stored at 808C before 20 lm sectioning on the
cryostat.
For the left (injected) eye of each rat, the sampling
procedure was as follows: 4 sections per slide, with 4
series and 1 in 5 between each row in the series in
peripheral regions, with every section collected
through the optic nerve head (ONH) and reverting
to 1 in 5 sampling again once past the ONH. For the
right (uninjected) eye of each animal, a more
restricted number of slides were taken through the
peripheral/central retina (to include the ONH).
Four slides spanning the central retina from 1
series of each left eye were stained using immunohis-
tochemistry (IHC) for anti-human nuclei and anti-
TRA-1-85 as described previously26 or anti-human–
specific nestin (Hs nestin), with 1 slide from the
central retina of an adjacent series in each left eye
processed in the absence of primary antibodies as a
negative control. One central slide (containing the
ONH) from the right eye of each animal also was
stained for anti-human markers. During this screen-
ing procedure the retina was counterstained with
DAPI to visualize nuclear layers and an antibody
against ML-opsin to visualize host cone morphology.
Immunostaining occurred in batches with a slide of
pelleted GS089 hRPC in each batch as positive
control (pellets prepared from hRPC fixed immedi-
ately upon cessation of transplants, cryopreserved,
frozen, and sectioned at 14 lm on the cryostat).
Upon location of surviving human cells in one
series, adjacent series of sections were used to
determine the phenotype of engrafted hRPC. The
source and optimal working dilution of each primary
antibody are listed in Table 1. When counterstaining
human cells with primary antibodies raised in mouse,
it sometimes was necessary to use a directly conju-
gated Alexa Fluor 488 anti-human nestin antibody.
In addition to the IHC staining detailed above, 1
slide from both eyes of each animal in this study was
hematoxylin and eosin (H&E) stained to assess the
general health of ocular tissue. This staining and
assessment was conducted independently by a UK-
based contract research organisation (Sequani Ltd.,
Ledbury, UK).
Assessment of Photoreceptor Preservation
by Measurement of ONL Thickness
The assessment of ONL preservation was deter-
mined for each eye using the series of slides processed
for anti-human markers. To visualize the nuclear
layers of the retina, images of a standardized area
(531.253 400 lm) were taken on the 40,6-diamidino-
2-phenylendole (DAPI) counterstain channel using a
Leica fluorescence microscope (Leica Camera, Wet-
zlar, Germany). Slides were coded so that the
observer was blinded to the experimental conditions
and three images were taken in the dorsal retina of
each eye, with the sampling position kept consistent
between eyes by always taking photographs in
sections where the ONH was visible. Measurements
were made at the thickest, most coherent point of the
ONL (when present) in each image, with ONL
thickness recorded in micrometers, and number of
cells. An average thickness then was calculated from
the three images of each eye.
Influence of Dexamethasone on Retinal
Microglia/Macrophages
A comparison of the OKR response between
animals that had received dexamethasone anti-
inflammatory treatment and those that had not
revealed a rather striking suppression of visual
function emanating from the vehicle-injected (left)
and uninjected (right) eyes of treated animals. Given
that microglia/macrophages have been shown to
persist in the subretinal space of RCS dystrophic rats
with preserved ONL/visual function but no detectable
human cells,23 we hypothesized that these cells may be
involved in a potential host retinal response to
dexamethasone.
To test this hypothesis, we performed subretinal
vehicle injections in the left eye of a small group of
RCS dystrophic rats (n ¼ 6, 23 days old) and then
gave them daily IP injections of either dexamethasone
(1.6 mg/kg/day, n ¼ 3) or saline (n ¼ 3) for 4 days.
Animals were monitored closely for any adverse
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effects and then perfused on the fourth day following
surgery. No adverse events were seen during this brief
dosing period and all animals appeared in good health
before tissue processing.
Both eyes from each animal were frozen and
sectioned at 20 lm as described above, with central
retinal sections (encompassing the ONH) collected
onto slides and processed for IHC to detect microglia/
macrophages as follows: endogenous peroxidase
activity was reduced by incubating slides for 10
minutes in 0.1 M PBS with 50% methanol and 0.3%
H2O2. Slides then were blocked with 5% normal horse
serum in 0.1 M PBS and 0.3% triton X-100 for 1 hour
and incubated overnight with the ED1 primary
antibody, which detects CD68 expressed in retinal
macrophages/microglia.23 Sections then were washed
with PBS and incubated for 2 hours with biotinylated
horse anti-mouse secondary antibody (1:100, Vector
Laboratories, Inc., Burlingame, CA). Avidin-biotin
signal amplification then was performed for 1 hour
using a Vectastain ABC kit (Vector Laboratories)
before visualization with a diaminobenzidine chro-
magen kit (DAKO chromagen kit; DAKO, Carpin-
tiera, CA). Sections were incubated for 5 minutes in
this chromagen mixture before stopping the reaction
with PBS and cover slipping with glycerol.
Six transmitted light images were taken on a Leica
microscope with associated camera and image-
grabbing software. These images were spaced equally
along the dorsal–ventral axis of the central retinal
section, with three sampling points above the ONH:
dorsal peripheral (DP), dorsal (D), dorsal central
(DC), and three below the ONH: ventral central
(VC), ventral (V), and ventral peripheral (VP). From
each image, a 277-lm length of retina was analyzed,
with a total of 1.7 mm length of retina sampled per
eye. Any pigmented tissue adjacent to the retina
(e.g., RPE and choroid) was removed and each
image was converted to grayscale. Image J (National
Institutes of Health, Bethesda, MD) then was used to
analyze the grayscale staining profiles, with the
threshold for inclusion of staining set at 0 to 112
for all images (where 0 ¼ black). The number of
profiles in each image was recorded, with only those
profiles above 30 lm2 in area included to avoid
counting any small fibers/artifacts in the image. In
addition to this semiautomated method, we also
counted the number of ED1-positive cells in each
image manually.
Safety Study
An independent safety study was conducted at a
contract research organization (CRO) according to
good laboratory practice (GLP). This study used
NIH-III nude mice, an immune-deficient model
(lacking natural killer cells/mature T and B cells),
Table 1. Primary Antibodies, Source, and Working Dilutions.
Antibody Host Source Code Dilution
bIII tubulin Mouse Abcam MAB5564 1:200
Crx Mouse Abnova Clone 4G11 1:1,000
ED1 (CD68) Mouse AbD Serotec Clone ED1 1:1,000
GFAP Rabbit DAKO Clone 6F2 1:100
ML-opsin Rabbit Millipore AB5405 1:5,000
Human nestin Mouse eBioscience Clone 10C2 1:1,000
Human nestin Alexa Fluort488 Mouse eBioscience Clone 10C2 1:50
TRA-1-85 Mouse DSHB Concentrate 1:250
Anti-human Nuclei Mouse Millipore MAB1281 1:1000
Otx2 Rabbit Millipore AB9566 1:1,000
Pax6 Rabbit BioLegend Poly19013 1:300
Rhodopsin Rabbit Abcam AB59260 1:1,000
Rhodopsin Mouse Gifta 4D2 1:50
Recoverin Rabbit Abcam AB5585 1:1,000
S-opsin Goat Santa Cruz SC-14363 1:500
Sox2 Rabbit Abcam AB97959 1:1,000
Vimentin Cy3 Mouse Sigma-Aldrich C9080 1:200
a Kind gift from R. Molday, University of British Columbia, Canada.
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which has been used to assess preclinical safety of
human cells for ocular application.15 Groups of NIH-
III mice received a 1 lL subretinal injection into the
left eye of 13 105 GS089 hRPC (n¼ 45), HBSS-NAC
vehicle (n ¼ 45), or the Y79 retinoblastoma cell line
(positive control, n¼ 46), with all right eyes remaining
uninjected. A fourth group of animals (n ¼ 45)
remained unoperated in both eyes. Cells were
prepared at ReNeuron on the morning of transplan-
tation and then shipped to the CRO surgery. The
clinical condition, body weight, and food consump-
tion of mice was monitored closely for 9 months (39
weeks) after grafting before euthanization using CO2
followed by cervical dislocation. Both eyes and organs
(Supplementary Table S1) were examined for macro-
pathology and histopathology following sectioning/
H&E staining.
The presence of human cells also was examined in
both eyes and other key organs (Supplementary Table
S2) of the hRPC-grafted mice by in situ hybridization
(ISH) for the human Alu sequence. The presence of
this sequence is a reliable indicator of human
xenograft survival.31 This work was conducted
independently under GLP by Histologix Ltd. (Not-
tingham, UK) and the reagents, staining protocol,
and specific conditions used for human Alu-ISH are
detailed in Supplementary Tables S3-S5. A total of 10
sections per eye and 2 sections per organ were stained
using the human Alu ISH technique. Positive and
negative Alu ISH probes were tested on additional
control eyes from WT mice that had an intravitreal
injection of hRPC (1lL of 13 105 cells/lL), ex-vivo,
immediately before fixation/processing for human
Alu ISH.
Statistical Analysis
For OKR data, the total amount of time spent
tracking during the two minutes anticlockwise or
clockwise was calculated and analyzed statistically
using 2-way ANOVA and Bonferonni post hoc tests.
To help equalize the variance and normalize the data,
before ANOVA analysis, all data were transformed
with the equation Y ¼ =(Yþ0.375).32 The ONL
thickness and number of ED1-positive profiles/cells
also were analyzed using 2-way ANOVA followed by
Bonferonni post hoc tests. For OKR and ONL,
analysis factors were eye (left/right) and cell dose. For
the analysis of ED1-stained material, ANOVA factors
were eye (left/right) and treatment (dexamethasone or
vehicle). All statistical analyses was performed using
GraphPad Prism (GraphPad Software, San Diego,
CA).
Results
hRPC Preserve Vision in Dexamethasone-
Treated RCS Dystrophic Rats
After 1 week of dexamethasone treatment approx-
imately 38% of animals (5 vehicle-injected rats [~33%]
and 9 hRPC-injected rats [~41%]) showed signs of ill
health and were removed from the study. Remaining
animals were tested for visual function by OKR at 12
weeks after grafting and analyzed by 2-way ANOVA.
This showed no significant differences between eye,
dose, or any interaction between these factors at the
lowest spatial frequency tested (0.125 C/D, Fig. 1A).
There was an interaction between eye and dose at the
intermediate grating (Fig. 1B, F1,42¼ 7.65, P¼ 0.008)
and fine vision was preserved at the highest spatial
frequency (0.5 C/D, Fig. 1C), with a significant effect
of eye (F1,42¼ 9.49, P¼ 0.004) and dose (F1,42¼ 11.27,
P ¼ 0.002). Bonferroni post hoc tests confirmed that
hRPC injection into the left eye of dexamethasone-
treated dystrophic rats significantly improved visual
tracking compared to either vehicle-injected left eyes
or fellow right eyes (P , 0.001, Fig. 1C). Although
ONL preservation appeared greatest in hRPC en-
grafted left eyes (Figs. 1D, 1E), this difference did not
reach statistical significance by 2-tailed unpaired t-
test.
Detecting a Dose Effect in Dystrophic Rats
without Dexamethasone
At 12 weeks after grafting, there was a significant
effect of dose at 0.125 C/D (F4,118¼ 3.75, P¼ 0.007),
with post hoc comparisons confirming elevated
tracking in the left eyes from animals dosed with 10
and 50 K hRPC (relative to left eyes from vehicle-
treated rats, P, 0.05, as indicated on Fig. 2A). At the
intermediate (0.25 C/D, Fig. 2B) and finest (0.5 C/D,
Fig. 2C) grating frequencies, eye was the only
significant factor (F1,118 ¼ 5.95, P ¼ 0.016 and F1,118
¼ 10.13, P¼ 0.002 respectively). At the finest grating,
despite a lack of significance between the dosage
groups of injected left eyes, a dose effect was found
for the highest (200 K) dosage group at the post hoc
level by comparing left eyes with fellow right eyes (P
, 0.05, Fig. 2C). As shown in Figure 2D, there was
clear evidence of ONL preservation in the left eyes of
dystrophic rats receiving cell injections. Analysis of
ONL thickness by 2-way ANOVA confirmed that eye
was a significant factor (F1,40¼44.00, P, 0.0001) but
not dose. However, post hoc analysis revealed that
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hRPC doses of 50 K and above resulted in
significantly more ONL preservation in left eyes
versus fellow right eyes (P , 0.05, Fig. 2E). Although
the mean ONL thickness at 12 weeks after grafting
was slightly lower in the vehicle-injected eyes of
dexamethasone-treated animals (compare Figs. 1E,
2E), this difference did not reach statistical signifi-
cance.
By 26 weeks after grafting, visual responsiveness of
dystrophic rats had diminished in all experimental
groups. At 0.125 C/D (Fig. 3A) and 0.25 C/D (Fig.
3B), eye was the only significant factor (F1,66¼9.63, P
¼ 0.003 and F1,66 ¼ 14.21, P ¼ 0.0004, respectively).
However, post hoc tests revealed that only the left
eyes treated with 100 K hRPC track better than fellow
right eyes at 0.125 C/D (P , 0.05, Fig. 3A). Head
tracking at 0.5 C/D was minimal from left eyes and
completely absent from untreated right eyes at 26
weeks after grafting (Fig. 3C), with no statistically
significant differences detected. As shown in Figures
3D to 3E, ONL appeared best preserved in the left
eyes of rats injected with a dose of 100 to 200 K
hRPC. Eye was a significant factor in ONL preser-
vation (F1,66¼ 17.19, P , 0.0001) and although there
was no overall effect of dose by 2-way ANOVA, at
the post hoc level, 100 to 200 K hRPC resulted in
significantly more ONL in left eyes versus fellow
uninjected right eyes (P , 0.05, Fig. 3E). Interesting,
the most significant difference in ONL thickness
between left and right eyes occurred in the 100 K
dosage group (P , 0.001, Fig. 3E), the only group to
show a significant difference between left and right
eye–mediated tracking (P , 0.05, Fig. 3A). Where
ONL preservation occurred in dystrophic rats at 26
weeks after injection, this was restricted to the dorsal
Figure 1. Subretinal injection of a single dose (50 K) of hRPC into dexamethasone-treated RCS dystrophic rats significantly preserves
vision 3 months after grafting, as assessed using the OKR. (A) At 0.125 C/D there is no effect of transplant or eye. (B) At 0.25 C/D there is a
significant interaction between transplantation and eye but no significance at the post hoc level. (C) At the highest spatial frequency (0.5
C/D), transplantation of hRPC significantly improves vision, with the 50 K (cell transplanted) left eyes tracking significantly better than
either vehicle-injected (0 K) left eyes or uninjected right eyes. (D) Representative histology images from the left eyes (L) of cell-injected
(50 K) and vehicle-injected (0 K) animals 14 weeks after grafting. (E) Quantification of ONL thickness 14 weeks after grafting reveals more
ONL in cell-grafted eyes. However, this does not reach statistical significance. Graphs show the mean 6 SEM with *P , 0.001 by
Bonferroni’s comparison. DAPI staining in blue. INL, inner nuclear layer; GCL, ganglion cell layer. Scale bars: 50 lm.
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retina (see low power images in Supplementary Fig.
S1).
Vision and ONL Thickness Remain Stable in
hRPC-Injected WT Rats
As part of the dose-ranging study, we also included
a group of WT rats receiving subretinal injection of
hRPC (50 K) into the left eye in the absence of
dexamethasone. We found no significant differences
in OKR head tracking or ONL thickness between
vehicle and hRPC-injected WT rats at either 12 (Fig.
4) or 26 (Supplementary Fig. S2) weeks after
injection.
HRPC Retain Nestin Expression During Long-
Term Survival In Vivo
As shown in Figure 5, on the day of transplanta-
tion, hRPC expressed a number of markers consistent
with a progenitor cell phenotype. All hRPC expressed
nestin, vimentin, and class III b-tubulin (bIII tubulin)
to various degrees and some cells also were positive
for glial fibrillary acidic protein (GFAP), Pax6, and
Figure 2. In the absence of dexamethasone treatment, subretinal injection of hRPC into RCS dystrophic rats significantly preserves
vision and ONL thickness 3 months after grafting. (A) At 0.125 C/D there is a significant effect of dose, with the 10 and 50 K groups
tracking more than the 0 K (vehicle) group at the post hoc level. (B) At 0.25 C/D there is a significant effect of eye but not dose. (C) At 0.5
C/D there also was an effect of eye with a dose effect apparent at the post hoc level, where only the eyes injected with 200 K cells tracked
significantly better than the uninjected right eyes. (D) Representative histology images from the left eyes (L) of vehicle-injected (0 K) and
cell-injected (10–200 K) animals 14 weeks after grafting show clear ONL preservation (arrows) above 50 K. (E) The ONL was significantly
preserved in left eyes injected with 50K cells (compared to uninjected right eyes). Graphs show the mean 6 SEM, with *P , 0.05, **P ,
0.01, ***P , 0.001 by Bonferroni’s comparison. DAPI staining in blue. Scale bars: 50 lm.
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Sox2. The hRPC were largely negative for the
photoreceptor/bipolar cell marker recoverin (Fig.
5C) and also lacked rhodopsin using the 4D2
antibody (Fig. 5D). A positive signal for rhodopsin
was detectable using a rabbit polyclonal antibody but
this was most likely nonspecific staining due to the
lack of colocalization with 4D2. Subpopulations of
hRPC were positive for the transcription factors Pax6
and Sox2 (Figs. 5E, 5F) but we were unable to detect
Crx, Otx2, ML-opsin, and S-opsin using the antibod-
ies listed in Table 1 (data not shown).
We initially used a mixture of anti-human nuclei
and TRA-1-85 to detect surviving human cells;
however, the signal provided by this method was
very weak, with no definition of cellular morphol-
ogy. This made it impractical to screen transplanted
rat eye sections in this way. Instead, because hRPC
express nestin ubiquitously, we used an antibody
specific to human nestin to locate grafted cells.
Using either method, we were unable to detect any
human cells in the left eyes from dexamethasone-
treated dystrophic rats (n¼ 7 left eyes sampled at 14
Figure 3. At 6 months after grafting, in the absence of dexamethasone treatment, hRPC injection slows the progressive decline of visual
function and ONL thickness in RCS dystrophic rats. (A) Visual function was preserved at the lowest spatial frequency (0.125 C/D), with a
significant effect of eye and post hoc significance restricted to eyes injected with 100 K hRPC. (B) At 0.25 C/D, eye remained a significant
factor but there was no further significance at the post hoc level. (C) At the finest grating frequency tested (0.5 C/D), dystrophic rats were
unable to track with the uninjected right eyes and although some left eye–driven tracking occurred, no significant differences were
detectable. (D) Representative histology images from the left eyes (L) of vehicle-injected (0 K) and cell-injected (10–200 K) animals 26
weeks after grafting showing ONL preservation (arrows). (E) The ONL was significantly preserved in left eyes injected with 100K cells
(compared to uninjected right eyes). Graphs show the mean 6 SEM, with *P , 0.05 and **P , 0.01 by Bonferroni’s comparison. DAPI
staining in blue, animal numbers in E match those used in (A–C). Scale bars: 50 lm.
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weeks). However, in the dose-ranging study, we
found human nestin-positive processes in left eyes
from 65% (13 of 20) of hRPC-injected dystrophic
rats at 14 weeks and approximately 77% (23 of 30)
of the remaining hRPC-injected dystrophic rats at
26 weeks after grafting. The percentage of left eyes
containing human processes per group were as
follows: 14 weeks (n ¼ 5/group) – 10 K (60%), 50
K (60%), 100 K (80%), and 200 K (60%), and 26
weeks (n¼ 5-7/group) – 10 K (~62%), 50 K (100%),
100 K (~71%), and 200 K (~75%). In WT rats we
found human nestin-positive processes in 80% (4 of
5 left eyes) of animals sampled at 14 weeks and in
70% (7 of 10 left eyes) of the remaining hRPC-
injected rats at 26 weeks. No human cells were
detected in any right eyes and, where present in left
eyes, hRPC typically spanned 4 to 12 eye sections in
one series.
Human nestin-positive processes were consistent-
ly negative for rhodopsin, ML-opsin, S-opsin, and
recoverin (data not shown). As shown in Figure 6,
hRPC retained strong nestin expression up to 6
months (26 weeks) in vivo. Human cells integrated
into the host inner retina, with occasional human
fibers detectable at the level of the outer plexiform
layer (Fig. 6A) but no evidence of human somas
within the ONL. Also, we could find no evidence of
subretinal masses of hRPC, as reported by Luo et
Figure 4. At 3 months after grafting, in the absence of dexamethasone treatment, subretinal injection of hRPC into WT rats had no
significant impact on either visual acuity. The rats tracked well at all spatial frequencies tested by OKR: 0.125 C/D (A), 0.25 C/D (B), and
0.125 C/D (C), with time spent tracking the visual stimulus not significantly affected by either hRPC transplantation (0 vs. 50 K) or eye (left
versus right). (D) Representative retinal images from the left (L) and right (R) eyes of vehicle-injected (0 K) and hRPC-injected (50 K)
animals. (E) There were no statistically significant differences in ONL thickness between either transplant group (0 vs. 50K) or between left
and right eyes. Graphs show the mean 6 SEM, DAPI-stained nuclei in blue. Scale bars: 50 lm.
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al.22 In dystrophic and WT retina, human processes
expressed GFAP (Figs. 6C, 6D), vimentin (Figs. 6E,
6F), and bIII tubulin (Supplementary Fig. S3) to
varying degrees. A similar pattern of colocalization
between these markers and human nestin also was
seen in rats killed at 14 weeks after grafting (data
not shown). Interestingly, we also found a consistent
upregulation of bIII tubulin in the retina of
dystrophic rats (Supplementary Fig. S3). As illus-
trated in Figure 6E and Supplementary Figure S3A,
the presence of hRPC did not always correlate with
ONL preservation and large autofluorescent mac-
rophages were seen commonly at apparent injection
sites, where ONL was preserved either side of a
discontinuity in lamination (arrows in Figs. 6A, 6C).
We also found some evidence of subretinal scarring
revealed by GFAP staining (arrow in Fig. 6E) and
human material along the vitreoretinal interface
(large arrows in Fig. 6 and Supplementary Fig. S3).
Dexamethasone Reduces Baseline Visual
Acuity in RCS Dystrophic Rats
By comparing OKR data from Figures 1C and
2C, it became apparent that there were exceptionally
low levels of baseline visual function to the finest
grating in dexamethasone-treated animals. When
the two 0.5 C/D data sets were compared directly
(Figs. 7A, 7B), we found that dexamethasone
reduced tracking in response to a sham injection
of vehicle (Fig. 7A) but not 50 K hRPC (Fig. 7B).
This effect of dexamethasone on the amount of
baseline tracking following vehicle injection was
significant by 2-way ANOVA (F1,42 ¼ 7.95, P ¼
Figure 5. Immunocytochemistry for retinal markers in sections through a pellet of hRPC, fixed immediately upon cessation of surgery.
All cells expressed nestin and bIII tubulin, with some positive staining for GFAP and variable levels of vimentin expression (A–C). Human
retinal progenitor cells were found to be largely negative for recoverin (red in [C]), negative for rhodopsin using the 4D2 antibody (green
in [D]) but positive for this opsin using a rabbit polyclonal antibody (red in [D]). As shown in adjacent sections, subpopulations of hRPC
expressed the retinal progenitor markers Pax6 and Sox2 ([E] and [F], respectively). Proteins of interest are color coded and colocalization
appears yellow. Cell nuclei stained blue with DAPI. Scale bars: 20 lm.
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0.007), with post hoc analysis confirming a reduc-
tion in the left eyes of dexamethasone-treated rats
and baseline tracking being completely abolished in
the right eyes (P , 0.05, Fig. 7A). However,
dexamethasone treatment appeared to have no
effect on the ability of hRPC to preserve left eye
tracking (Fig. 7B), with eye being the only signif-
icant factor in this comparison (F1,48 ¼ 10.44, P ¼
0.002). These data show that hRPC transplantation
can preserve fine vision independently of any
vehicle-related sham effect. Interestingly, the right
eyes of cell-grafted dystrophic rats also produced
Figure 6. In the absence of dexamethasone, hRPC survive for 6 months following subretinal injection into RCS dystrophic and wild type
rats. Representative images from left eyes showing hRPC stained green with an antibody to human-specific nestin (Hs Nestin) 6 months
after grafting into the RCS dystrophic (A, C, E) and WT (B, D, F) retina. Human cells were located in the inner retina where they extend
processes into IPL, with human material also seen at the vitreoretinal interface (large arrows in [A] and [B]). Human processes were
negative for M/L opsin but positive for GFAP and vimentin to varying degrees (yellow colocalization in [C–F]). Small arrows in (A) and (C)
indicate macrophages in the vicinity of the injection site, while arrowheads highlight hRPC processes extending along the outer plexiform
layer in (A). Images in (A) and (C) are from rats injected with 200 K hRPC, while all others are from rats injected with 50 K hRPC. Arrow in (E)
indicates GFAP-positive subretinal scarring. IPL, inner plexiform layer, outer segments (OS). DAPI staining in blue and proteins of interest
color-coded. Scale bars: (A–B) 200 lm, (C–F) 50 lm.
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almost no baseline tracking following dexametha-
sone treatment (Fig. 7B).
Dexamethasone Treatment Reduces the
Number of Microglia/Macrophages in Both
Eyes of Vehicle-Injected RCS Dystrophic Rats
Based on previous observations that ED1 (CD68)–
positive microglia/macrophages appear to preserve
retinal structure and visual function in RCS dystro-
phic rats,23 we hypothesized that dexamethasone also
may exert its effect on baseline visual function
through modulation of this cell type. So, given that
animals appeared in good health within the first week
of dexamethasone treatment, we compared ED1
staining in two groups of young (23 days old) RCS
rats in which the left eyes had been vehicle-injected
and animals had received 4 daily IP injections of
either dexamethasone or saline.
As shown in Figure 7C, using automated analysis,
we found a pronounced reduction in the number of
ED1-positive cellular profiles in vehicle-injected left
eyes and uninjected right eyes of dexamethasone-
treated rats. Dexamethasone was a significant factor
by 2-way ANOVA (F1,8¼ 25.24, P¼ 0.001), while eye
Figure 7. Dexamethasone treatment reduces baseline visual acuity in RCS dystrophic rats. At the highest spatial frequency tested (0.5 C/
D), dexamethasone was a significant factor, reducing the amount of time spent head tracking by vehicle (0 K)–injected left eyes (P, 0.05)
and abolishing the head tracking response from uninjected right eyes (A). In contrast, the level of high spatial frequency head tracking
was maintained in the presence of dexamethasone following 50 K hRPC injections into the left eye (B). A brief period of dexamethasone
exposure (4 days of IP injection DEX into 23-day-old RCS dystrophic rats) significantly reduced the number of CD68 (ED1)–positive
profiles compared to systemic saline injected (SAL) controls in left (vehicle-injected) and right (uninjected) eyes (C). This effect was
significant across several regions of dorsal and ventral retina (D). Representative ED1-stained images from left (vehicle-injected) and right
(uninjected) eyes are shown below the graphs (all from dorsal retina). ED1-positive staining is brown. Graphs show the mean 6 SEM with
post hoc significance as indicated: *P , 0.05; **P , 0.01. Scale bars: 50 lm.
13 TVST j 2016 j Vol. 5 j No. 4 j Article 6
Semo et al.
Downloaded From: http://tvst.arvojournals.org/pdfaccess.ashx?url=/data/Journals/TVST/935417/ on 10/18/2016
was not, with post hoc tests confirming that
dexamethasone treatment reduced ED1-positive pro-
files in the left and right eyes compared to saline
controls (P , 0.05, Fig. 7C). Because there were no
significant differences between left and right eye, data
from both eyes were amalgamated for a regional
analysis (Fig. 7D). This showed that dexamethasone
(F1,60¼ 49.13, P¼,0.0001) and retinal region (F5,60¼
3.50, P ¼ 0.008) were significant factors, with a
reduction in ED1-positive profiles across the dorsal-
ventral extent of retina (P , 0.05, Fig. 7D). An
independent manual count of ED1-positive cells gave
similar results, with dexamethasone treatment and
retinal region being significant factors (F1,60 ¼ 20.57,
P¼,0.0001 and F5,60¼ 5.58, P¼ 0.008, respectively,
data not shown). Representative images of ED1
staining from left and right eyes of both treatment
groups are shown at the bottom of Figure 7. These
findings suggested that dexamethasone works by
reducing the migration of microglia/macrophages
towards actively degenerating rods/cones in the outer
retina.
Safety Assessments
In the rat eyes examined above by DAPI/H&E (left
and right eyes from 104 animals), we could find no
evidence of uncontrolled cell growth, tumor forma-
tion or unexpected alterations to retinal structure.
Furthermore, in an independently conducted GLP
tumorigenicity study in NIH-III mice, there was no
effect of hRPC injection on body weight gain, food
consumption, mortality, or clinical observations of
the eyes up to 9 months after grafting. There also were
no hRPC-related neoplastic or nonneoplastic changes
detected in any eyes or organs. This was not the case
in the Y79-positive control group, where mice
developed neoplastic changes (i.e., retinoblastoma)
in the left eye, thereby confirming the validity of this
model for tumorigenicity assessments.
Further investigation of the eyes/organs from
NIH-III mice receiving hRPC injections into the left
eye found no evidence of human cells in the organs or
right eyes. This was with the exception of a single Alu-
positive cell found in a right eye section from 1 female
animal (data not shown). At 9 months after grafting,
human Alu-positive cells were found in the left eyes of
approximately 33% of mice (15 of 45). Supplementary
Figure S4 shows the specificity of the Alu-positive
probe used in this study. The number of surviving
human cells per left eye ranged from 1 to75 (mean, 9.5
6 5 SEM) and they were found within the inner retina
(Supplementary Fig. S4C).
Discussion
We showed that the hRPC line GS089 is safe and
effective in reducing the rate of retinal degeneration
and visual deterioration in RCS dystrophic rats. This
efficacy result agrees with a recent study, which
examined a different hRPC line (GS086) 3 months
after grafting into the RCS dystrophic rat model.22
Like the study by Luo et al.22 (which used dexameth-
asone), we were also able to detect a clear preserva-
tion of fine vision at 3 months after grafting in
dexamethasone-treated rats. However, this occurred
in the absence of detectable human cells in the present
study, a finding that agrees with previous reports of
visual preservation in RCS rats in the absence of
surviving human iPSC-RPE cells.23
For ethical reasons, our dose-ranging study was
performed in the absence of dexamethasone treat-
ment. This study established that only 10,000 to
50,000 hRPC were required to preserve visual
responses to the broadest grating at 3 months after
grafting, with 50,000 cells proving sufficient to
preserve ONL thickness at the same time-point.
However, we found that higher doses of hRPC
(.100,000) were required to preserve fine vision at 3
months after grafting and visual function/ONL
thickness at 6 months after grafting. These findings
are comparable to those from the only other
published preclinical dose-ranging study in RCS
rats, which found that preservation of visual
response could occur using just 5000 human ES-
derived RPE cells and appeared optimal at 50,000
cells.15
The disparity between OKR and ONL data at 3
months after grafting in the dose-ranging study may
be due to several factors. Firstly, a lack of
significance in tracking from the 100 K hRPC-
treated eyes may be due to the higher variance in
OKR data and baseline tracking caused by dexa-
methasone omission. Also, other studies have shown
that ONL preservation does not always correlate
with preserved retinal function.33,34 Secondly, the
disparity between poor ONL preservation and good
levels of tracking to the lowest spatial frequency in
left eyes from the 10 K dosage group at 3 months
may simply reflect a lack of sensitivity of our
histologic sampling method. However, in support of
this method, the OKR and ONL data are well
correlated for left eyes in the 100 K dosage group at
6 months after grafting.
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Dexamethasone Treatment Reduces Baseline
Visual Acuity and Microglia/Macrophages
An unexpected finding in the present study was the
effect of dexamethasone treatment on baseline visual
acuity in RCS dystrophic rats, with dexamethasone
abolishing visual responses to the finest spatial
frequency in sham-injected animals. This effect is
the opposite of that seen following intravitreal
injections of the proinflammatory cytokine IL-1b,
which preserves visual acuity and ONL thickness in
RCS dystrophic rats.35 As the dexamethasone dose
used in the present study is likely to exert anti-
inflammatory effects, our new findings are consistent
with an important role for the inflammatory response
in preserving vision during retinal degeneration. This
also is consistent with the protective role proposed for
microglia in the early stages of neurodegeneration in
other diseases of the central nervous system.36
The effect of dexamethasone presumably would
have made it easier to detect any cell-based preserva-
tion of vision in the other RCS rat studies using this
drug.14,15,22 This is because the measure used to
determine optokinetic visual acuity in these studies
involves measuring the maximum spatial frequency a
rat can detect, rather than the total time spent
tracking at different grating frequencies. Interestingly,
although the preclinical work for the recent human
ES-RPE trial involved dexamethasone, anti-inflam-
matory treatment was not noted in the clinical
protocol.21 As such, the initial efficacy obtained from
human ES-RPE grafting in patients with advanced
AMD would presumably include a significant sham-
derived component. However, longer-term follow up
of these patients indicates the expansion of pigmented
cells and a sustained improvement in visual acuity.37
We found that dexamethasone administration
significantly reduces the number of ED1 (CD68)–
positive microglia/macrophages in the RCS dystro-
phic retina. These cells previously have been shown to
phagocytose photoreceptor debris in the subretinal
space of RCS dystrophic rats, where they also have
been implicated in the preservation of retinal struc-
ture/function in the absence of grafted human cells.23
Dexamethasone also has been shown to reduce the
phagocytic capacity of macrophages38–40 and the
trophic response of microglia to brain injury.41 By
reducing the number of macrophages/microglia,
dexamethasone treatment also would be reducing a
potential supply of trophic factors,42,43 which other-
wise could enhance vision through preservation of
photoreceptor structure.13 However, within the limi-
tations of the present study, we were unable to find
statistical evidence for a dexamethasone-mediated
acceleration of ONL loss. An alternative explanation
to explain how microglia may normally act to
enhance baseline visual function in RCS rats could
involve some kind of neurotrophin-mediated en-
hancement of retinal acuity circuits.44–46
Intermediate Filament Expression Is
Retained by Xenografted hRPC
The expression profile of hRPC before grafting
was consistent with that previously reported for
human retinal progenitor cells.11,12,16,18 In addition
to bIII tubulin and the intermediate filaments nestin
and vimentin, we also were able to detect the
expression of the intermediate filament GFAP in
some hRPC before grafting. This is consistent with
previous reports of GFAP expression in cultured
hRPC11,18 and of nestin, bIII tubulin, and GFAP
colocalization in human neural progenitor cells.47
Following subretinal transplantation into RCS
dystrophic and normal WT rats, hRPC integrated
into the inner retina and survived for up to 6
months after grafting in the absence of dexameth-
asone treatment. This is in line with previous reports
of neural progenitor cell integration into the rodent
retina in the absence of this drug.26,30 As described
for hRPC previously,22,48 GS089 cells retained
expression of nestin in vivo. However, these hRPC
also expressed vimentin, GFAP, and bIII tubulin to
varying degrees. This is an interesting and important
observation, with two potential interpretations: 1,
the hRPC remain in their undifferentiated progen-
itor-like state, or 2, they have differentiated along
the glial lineage.
In support of the second possibility, it has been
shown that retinal Muller cells express nestin and
vimentin in human foetal retina at 15 to 19 weeks of
gestation and that hRPC can preferentially differen-
tiate towards a glial fate during neurosphere differ-
entiation experiments.49
The morphology of the integrated hRPC and their
expression of nestin, vimentin, and GFAP certainly is
consistent with a glial phenotype, as none of these
markers would be expected in differentiated neurons.
However, because we were using nestin to locate
human cells it remains possible that a different
subpopulation of hRPC differentiated along neural/
photoreceptor lineages, which were undetectable in
the current experiment. In contrast to a previous
study in rhodopsin knockout mice, we were unable to
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find any evidence of opsin expression by the engrafted
hRPC. This discrepancy also could be due to
differences between the hRPC line, animal models
or opsin antibodies used in the two studies. However,
in a recent study looking at another hRPC line
(GS086), the human cells survived for 3 months after
injection into RCS rats, integrated into the retina,
maintained vision by OKR, and expressed nestin.22
An absence of hRPC integration into the ONL and
lack of photoreceptor marker expression by hRPC in
the study of Luo et al.22 and our current study
strongly suggests that hRPC-mediated preservation of
vision in RCS rats is mediated by trophic support,
which either preserves photoreceptor structure or
increases visual acuity somehow from existing retinal
circuitry.46
Conclusions
In conclusion, the GS089 hRPC line appears safe
and preserves retinal structure/vision at an optimal
dose of 50,000 to 100,000 cells following subretinal
injection into a widely used preclinical model of
degenerative retinal disease. Although the exact
mechanism of hRPC-derived neuroprotection is
unclear at present, it may involve either direct
neurotrophic release from the human cells or their
ability to attract and/or retain neuroprotective
macrophages. Importantly, we also showed that
hRPC are capable of integrating into the normal
WT retina and that their presence does not
adversely affect retinal structure or visual function.
This is encouraging for the deployment of hRPC in
less affected regions of the retina at early stages of
retinal disease or even in normal regions of
peripheral retina, where they potentially could be
used for the sustained intraocular delivery of
therapeutic molecules.
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